February 2, 2026

Abstract HUP16: Sociodemographic Mortality Trends and Disparities Related to Coexisting Pancreatic Cancer and Cerebrovascular Disease in the United States From 1999 to 2019 – A Nationwide Analysis

Key Result

The age-adjusted mortality rate for individuals with both pancreatic cancer and cerebrovascular disease increased from 0.32 in 1999 to 0.43 in 2019, with significant disparities by race and sex.

Key Points

This research aims to analyze mortality trends related to coexisting pancreatic cancer and cerebrovascular disease over two decades in the U.S.
Data extracted from the CDC WONDER database
Age-adjusted mortality rates calculated for individuals over 25 years from 1999 to 2019
Use of ICD-10 codes to identify relevant fatalities
Trends analyzed by year, sex, race/ethnicity, census region, and metropolitan status
Annual percent change computed using Joinpoint regression
A total of 14,701 deaths identified where both conditions were involved
Overall age-adjusted mortality rate was 0.33 per 100,000 population
Mortality rate rose from 0.32 in 1999 to 0.43 in 2019
Men had higher mortality rates than women
Black or African American population exhibited the highest mortality rate at 0.52 per 100,000

Structured PICO

Population

14,701 individuals aged > 25 years in the United States who died with coexisting pancreatic cancer and cerebrovascular disease (CeVD) listed as underlying or contributing causes of death between 1999 and 2019.

Outcome

Age-adjusted mortality rates (AAMR) per 100,000 population and annual percent change (APC)hard clinical

Mortality related to coexisting pancreatic cancer and cerebrovascular disease in the US has increased significantly from 2013 to 2019, with notable disparities affecting men, Black populations, and nonmetropolitan areas.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Introduction: Pancreatic cancer increases the risk of cerebrovascular disease (CeVD) through inflammatory and prothrombotic pathways. Despite this established risk, mortality trends related to these two conditions have not been explored. This study aims to explore the national mortality trends over two decades in individuals with coexisting pancreatic cancer and CeVD. Methods: The data was extracted from the Centers for Disease Control and Prevention database, CDC WONDER. The age-adjusted mortality rates (AAMR) per 100,000 population was calculated from 1999 to 2019 among individual aged > 25 years. Using the ICD-10 codes C25 and I60-I69 for pancreatic cancer and CeVD respectively, those fatalities were identified where both conditions were listed as either the underlying or contributing cause of death. We analyzed the trends by year, sex, race/ethnicity, census region, and metropolitan status. Using the Joinpoint regression, we calculated the annual percent change (APC) in AAMR with 95% confidence intervals. Results: From 1999 to 2019, a total of 14,701 deaths occurred where both CeVD and pancreatic cancer could be listed as the either underlying or contributing cause. The overall AAMR was 0.33 per 100,000 population. The AAMR increased from 0.32 in 1999 to 0.43 in 2019, showing a stable trend from 1999 to 2013 (APC: -0.82, p = 0.07), followed by a noticeable increasing trend from 2013 to 2019 (APC: 5.47, p < 0.001). Men had higher AAMR (0.37) than women (0.29). The Black or African American population had the highest AAMR (0.52), followed by White (0.33), American Indian or Alaska Native (0.30), Asian or Pacific Islander (0.26), and Hispanic or Latino (0.21). Among census regions, the Midwest (0.34) and the West (0.34) had the highest AAMRs, followed by the South (0.32) and the Northeast (0.31). AAMR in nonmetropolitan areas (0.35) was higher compared to that in metropolitan (0.33) areas. Conclusion: In conclusion, the mortality related to coexisting pancreatic cancer and cerebrovascular disease has increased throughout the study period. The study also highlights important sociodemographic disparities. These findings underscore the need for early screenings and urgent interventions among vulnerable cohorts to control preventable mortality.